Diagnosis and Treatment of Dry Eye Syndrome
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 4.033 alerts
Get alerted when Policy MP 4.033 changes without checking for updates manually.
Monitor payer policy activity
Defines Capital Bluecross coverage stance for diagnostic and treatment technologies for dry eye syndrome, including eyelid thermal pulsation systems, intense pulsed light, and near-infrared meibography; applies to applicable Capital Bluecross products as noted. Affects providers seeking reimbursement for these services.
No material clinical or coverage changes in this revision.
Coverage Criteria and Policy Stance
Investigational therapies
Covered when ALL of the following are met
Insufficient evidence to support a general conclusion concerning the health outcomes or benefits.
Investigational diagnostics
Insufficient evidence to support a general conclusion concerning the health outcomes or benefits.
Thermal pulsation / device therapies
Coverage stance and evidence summary for eyelid thermal pulsation and related device therapies:
Observational studies report sustained effects up to 3 years for some outcomes; additional well-designed RCTs with adequate masking, standardized testing, and longer follow-up are needed. Procedure codes for these device therapies are listed as investigational and therefore not covered.
This policy explicitly designates certain therapies and diagnostics as investigational. Specifically, eyelid thermal pulsation therapy and intense pulsed light (IPL) with subsequent meibomian gland expression for the treatment of dry eye syndrome are classified as investigational and therefore not supported as medically necessary in this policy segment. The document also states that near-infrared dual imaging (meibography) of the meibomian glands is investigational. The policy rationale is that there is insufficient evidence to draw general conclusions about improved health outcomes or clinical benefit for these interventions.
Certain procedure codes associated with device-based therapies for meibomian gland dysfunction are identified in the policy as investigational — not covered. The policy lists these procedure codes under an investigational/not-covered section and notes that use of those codes may result in claim denials because the services they describe are not supported by sufficient evidence in this policy segment.
The designation of these interventions as investigational is based on the policy’s evidence assessment: available studies, including randomized trials and systematic reviews, do not provide sufficient, high-certainty evidence to conclude a net health benefit. As a result, these therapies are considered investigational due to insufficient evidence to support their effectiveness in improving clinical outcomes for dry eye related to meibomian gland dysfunction.
Eyelid thermal pulsation therapies (device-based heat-plus-expression treatments such as those referenced in the policy) are specifically called out as investigational. The policy treats procedure codes describing these eyelid thermal pulsation services as investigational and therefore not covered, and it warns providers that claims for these codes may be denied when submitted under the covered products governed by this policy.
Device & Procedure Coding
| LipiFlow® Thermal Pulsation System | LipiFlow® Thermal Pulsation System — For the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction (MGD); approved 2011 (DEN100017). |
| iLux® System | iLux® System — For the application of localized heat and pressure therapy in adult patients with chronic diseases of the eyelids, including MGD; cleared 2017 (K172645). |
| Systane® iLux2® | Systane® iLux2® — For the application of localized heat and pressure therapy in adult patients with Meibomian Gland dysfunction; cleared 2020 (K200400). |
| TearCare® System | TearCare® System — For the application of localized heat and pressure therapy in adult patients with evaporative dry eye disease due to MGD when used in conjunction with manual expression; cleared 2021 (K213045). |
| TearCare® MGX™ | TearCare® MGX™ — For the application of localized heat therapy in adult patients with evaporative dry eye disease due to MGD when used in conjunction with manual expression; cleared 2023 (K231084). |
| 0563T | 2020 code added to policy (mentioned in policy history) |
| No codes listed |
Provider Responsibilities and Billing Implications
Check product‑specific prior authorization
This policy applies only to certain Capital BlueCross programs and products; applicability varies by product and may be subject to different benefit rules (for example, FEP PPO refers to the FEP Medical Policy Manual). Verify the member’s specific product and any product-specific prior authorization requirements before scheduling services.
- See member benefit documents and product-specific manuals (e.g., FEP Medical Policy Manual) for prior authorization requirements.
- Do not assume policy applicability is uniform across all Capital BlueCross products.
Investigational procedure codes may affect prior authorization
Some procedure codes for therapies described as investigational in this policy are labeled not covered; use of those codes may affect prior authorization and claim adjudication. Confirm member benefit determination and PA requirements before submitting codes for investigational treatments.
- Investigational procedure codes listed as not covered may result in denial or PA not being granted.
- Prior authorization may still be required or denied based on member benefit terms and medical necessity.
AAO: thermal pulsation/IPL are step‑2 therapies
The American Academy of Ophthalmology Preferred Practice Pattern places thermal pulsation therapies as second‑line (step 2) options after an inadequate trial of conservative (step 1) measures such as lid hygiene, environmental/dietary changes, removal of offending agents, education, and ocular lubricants.
- Thermal pulsation and (previously) IPL are considered step 2 therapies when step 1 measures are inadequate.
- Step 1 measures include lid hygiene, dietary/environmental modifications, removal of offending agents, patient education, and ocular lubricants.
No explicit step therapy requirements in this policy
This policy segment does not impose explicit step therapy requirements; it only notes AAO guidance that thermal pulsation/IPL are considered step 2 after conservative measures. There is no policy‑specified mandatory step sequence or required documented trials listed here.
- No explicit step therapy protocol, required durations, or mandatory trials are specified in this document segment.
- Follow product and member benefit rules for any step therapy requirements beyond this policy.
Verify product variations and document benefit determinations
Policy applicability and coverage may vary by product administered by Capital BlueCross; providers must verify product‑specific benefit variations and documentation requirements (e.g., FEP PPO directs providers to the FEP Medical Policy Manual).
- Verify the member’s product and any referenced benefit manuals prior to service.
- Document product‑specific coverage determinations in the medical record and prior authorization submission as applicable.
Coding identification does not guarantee coverage
Coding information in this policy is not all‑inclusive; identification of a code in the document does not guarantee coverage. Coverage is determined by member benefit terms and medical necessity, and codes are subject to change.
- Do not assume that listing or mentioning a code implies coverage for that code.
- Confirm current coding, reimbursement rules, and member benefit terms before billing.
Denial risk for investigational eyelid/device services
Claims for eyelid thermal pulsation therapy, intense pulsed light with subsequent meibomian gland expression, and near‑infrared dual imaging of the meibomian glands may be denied because these services are considered investigational with insufficient evidence to support benefit.
- These interventions are described in the policy as investigational and therefore carry a risk of denial.
- Confirm member benefits and consider alternative, covered treatments when appropriate.
Investigational procedure codes are not covered
The policy identifies certain procedure codes for specific device therapies as investigational and therefore not covered; use of those investigational procedure codes may result in denial.
- Procedure codes listed under 'Investigational, therefore not covered' are not covered per this policy segment.
- Prior to billing, confirm whether a procedure code used for eyelid thermal pulsation, IPL with MGE, or meibography is listed as investigational and not covered.
Background and Rationale
Meibomian gland dysfunction (MGD) is the most common cause of dry eye syndrome and prevalence increases with age. Standard management includes conservative measures such as warm compresses, eyelid hygiene, manual gland expression, and pharmacologic options. Device-based approaches — including eyelid thermal pulsation systems and intense pulsed light (IPL), and diagnostic near-infrared meibography — are newer options intended to warm and express meibomian glands or to image gland structure. The policy summarizes evidence from randomized trials and systematic reviews but concludes that current evidence is of limited certainty and does not demonstrate clear net health benefit for these device-based therapies.
Definitions of Key Procedures and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.